Objective
Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). However, although surgical techniques and postoperative care have greatly advanced, renal transplantation is not empty of challenges.
The most important challenge is to achieve the long-term survival of the transplanted organ. Graft survival depends on the ability of the recipe of not rejecting the “foreign organ”. Rejection is a naturally occurring process triggered by a biological response of the immune system, which main function in the body is to defend it against infectious organisms and other invaders. As such, the immune system is prepared to reject a “foreign organ”, something that is nowadays prevented by prescribing immunosuppressive therapies to the patients for their whole life. However, the use of immunosuppressive therapies entails important problems. On one side, suppressing the immune system implies severe side effects like opportunistic infections, cancer and other severe malignancies. On the other side, even under immunosuppressive therapies, about 50% of transplanted kidneys are lost during the first 10 years and this is because of an immune response usually described as chronic rejection. Therefore, the major challenges in ESKD deal with avoiding the side effects associated with immunosuppressant drugs and avoiding chronic rejection.
In the TRANSBIO project we aim at bringing to the healthcare market a technology for efficient clinical management of patients undergoing a kidney transplant based on a simple and non-invasive blood test.
Considering that worldwide, the number of people receiving renal transplantation annually is estimated at about 80,000 people, growing by approximately 6% annually and representing a prevalence of about 700 patients per million population, or what is the same about 5 million people living with a transplanted kidney, the TRANSBIO business opportunity seems unquestionable.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- medical and health sciences basic medicine immunology
- medical and health sciences health sciences personalized medicine
- medical and health sciences clinical medicine transplantation
- medical and health sciences clinical medicine nephrology kidney diseases
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
28760 TRES CANTOS MADRID
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.